@article{oai:soar-ir.repo.nii.ac.jp:00003895,
 author = {Katoh,  Nagaaki and Matsuda,  Masayuki and Miyazaki,  Daigo and Gono,  Takahisa and Yazaki,  Masahide and Ikeda,  Shu-ichi},
 issue = {3},
 journal = {Amyloid-Journal of Protein Folding Disorders},
 month = {},
 note = {This is an electronic version of an article published in Amyloid 2009, Vol. 16, No. 3 : Pages 178-180. Amyloid is available online at: http://informahealthcare.com/doi/pdf/10.1080/13506120903090940, We report a patient with AH amyloidosis associated with lymphoplasmacytic leukemia that has remained in a stable state with a nephrotic syndrome for 17 months since the commencement of cyclic rituximab therapy aimed at suppression of pathogenetic gamma heavy chains. Free light chains in serum and CD20-positive cells in peripheral blood were useful as hematological markers in the patient. Rituximab might be a potent therapeutic option for AH amyloidosis associated with a B-cell lymphoproliferative disorder., Article, AMYLOID. 16(3):178-180 (2009)},
 pages = {178--180},
 title = {Rituximab therapy in nephrotic syndrome due to AH amyloidosis},
 volume = {16},
 year = {2009}
}